131801-69-9Relevant articles and documents
Synthesis and crystal structure of 1-(cyano(4-methoxyphenyl)methyl) cyclohexyl acetate
Mantelingu,Kavitha,Rangappa,Naveen,Sridhar,Prasad, J. Shashidhara
, p. 121 - 129 (2007)
The title compound, C17H21NO3, was synthesized by the acetylation of the hydroxy group of 1-(cyano(4-methoxyphenyl)methyl)cyclohexanol, which was formed by the reaction of 4-methoxyphenyl acetonitrile with cyclohexanone. The compound was characterized spectroscopically, and the structure was investigated by X-ray crystallography. The compound crystallizes in the orthorhombic crystal class in the space group Pbca with cell parameters a = 13.412(6) A, b = 12.398(14) A, c = 19.026(19) A and V = 3164(5) A3 for Z = 8. The cyclohexane ring is in a chair conformation. The structure exhibits intermolecular hydrogen bonds of the type C-H....N and C-H....O. Copyright Taylor & Francis Group, LLC.
Simple and an efficient method for the synthesis of 1-[2-dimethylamino-1- (4-methoxy-phenyl)-ethyl]-cyclohexanol hydrochloride: (±) venlafaxine racemic mixtures
Basappa,Kavitha,Rangappa
, p. 3279 - 3281 (2004)
A novel synthetic method was developed for the synthesis of venlafaxine using inexpensive reagents. An improvement in the method, in the yield was achieved for the conversion of the venlafaxine. This is an improved version, simple and efficient method for the large-scale synthesis of venlafaxine.
Method for industrially producing venlafaxine hydrochloride
-
Paragraph 0028; 0062-0069, (2021/09/26)
The invention discloses a method for industrially producing venlafaxine hydrochloride, and relates to the technical field of drug organic synthesis. The method has the advantages of easily available raw materials of the whole synthetic route, mild reaction conditions, simple and convenient operation, high yield, environment friendliness and good repeatability of the preparation method, and can be used for preparing venlafaxine hydrochloride with high yield and high purity.
Preparation method of venlafaxine amine impurity
-
Paragraph 0016; 0033-0035, (2021/05/12)
The invention discloses a preparation method of a venlafaxine amine impurity, and relates to the technical field of organic synthesis of medicines. P-methoxybenzyl cyanide and cyclohexanone are used as starting raw materials, condensation reaction is performed under the action of a phase transfer catalyst and alkali to obtain a compound 1, dehydration reaction is performed on the compound 1 under the action of acid to obtain a compound 2, and reduction reaction is conducted on the compound 2 under the action of a reducing agent to obtain an amine impurity I. The venlafaxine amine impurity (amine impurity I) with the structure is disclosed and successfully synthesized firstly, the purity of the venlafaxine amine impurity reaches 99% or above, and a high-purity impurity reference substance is provided for detection and content control of the impurity in venlafaxine hydrochloride medicine.
SUBSTITUTED ARYLUREA COMPOUNDS FOR INDUCING APOPTOSIS AND COMPOSITION FOR ANTICANCER COMPRISING THE SAME
-
Paragraph 0119-0123, (2021/08/17)
The present invention relates to a substituted arylurea compound inducing apoptosis and an anticancer composition comprising the same. The present invention relates to a novel compound capable of preventing, treating and alleviating cancer diseases such as prostate cancer, breast cancer, lung cancer, colorectal cancer, and skin cancer by inhibiting apoptosis of cancer cells and inhibiting proliferation of cancer cells.
Preparation method of venlafaxine impurity E (by machine translation)
-
Paragraph 0025; 0029, (2020/09/30)
The invention belongs to the technical field of organic synthesis, and relates to a preparation method of venlafaxine impurity E, which comprises (1) a condensation reaction, (2) a reduction reaction and (3) a ring-forming reaction. The method for synthesizing venlafaxine impurity E is less in steps, high in product purity, safe in reaction, less in waste liquid, simple in post-treatment, convenient to operate and convenient for industrial production. (by machine translation)
Method for preparing pharmaceutical intermediate with hydrotalcite material by catalysis
-
Paragraph 0052; 0054; 0058; 0060; 0062; 0063; 0064; 0065, (2018/11/22)
The invention belongs to the technical field of medicine, and particularly relates to a method for preparing a pharmaceutical intermediate with a hydrotalcite material by catalysis. The method includes first utilizing lithium fluoride as a modifier to modify the Zn/Al hydrotalcite material to obtain a hydrotalcite-supported lithium fluoride material. The hydrotalcite-supported lithium fluoride material can catalyze 4-methoxybenzyl cyanide and cyclohexanone to have condensation reaction to prepare 1-hydroxycyclohexyl-4-methoxybenzyl cyanide. The defects in the prior art of harsh reaction conditions, low yield and high environment pollution in the preparation process of overcomes the harsh reaction conditions in the preparation of a PRISTIQ and/or venlafaxine framework are overcome.
Selective Hydrogenation of Nitriles to Primary Amines Catalyzed by a Polysilane/SiO2-Supported Palladium Catalyst under Continuous-Flow Conditions
Saito, Yuki,Ishitani, Haruro,Ueno, Masaharu,Kobayashi, Shū
, p. 211 - 215 (2017/04/21)
Hydrogenation of nitriles to primary amines with heterogeneous catalysts under liquid-phase continuous-flow conditions is described. Newly developed polysilane/SiO2-supported Pd was found to be an effective catalyst and various nitriles were converted into primary amine salts in almost quantitative yields under mild reaction conditions. Interestingly, a complex mixture was obtained under batch conditions. Lifetime experiments showed that this catalyst remained active for more than 300 h (TON≥10 000) without loss of selectivity and no metal leaching from the catalyst occurred. By using this continuous-flow hydrogenation, synthesis of venlafaxine, an antidepressant drug, has been accomplished.
Screening of quinoline, 1,3-benzoxazine, and 1,3-oxazine-based small molecules against isolated methionyl-tRNA synthetase and A549 and HCT116 cancer cells including an in silico binding mode analysis
Bharathkumar, Hanumantharayappa,Mohan, Chakrabhavi Dhananjaya,Rangappa, Shobith,Kang, Taehee,Keerthy,Fuchs, Julian E.,Kwon, Nam Hoon,Bender, Andreas,Kim, Sunghoon,Basappa,Rangappa, Kanchugarakoppal S.
, p. 9381 - 9387 (2015/09/15)
Elevated activity of methionyl-tRNA synthetase (MRS) in many cancers renders it a possible drug target in this disease area, as well as in a series of parasitic diseases. In the present work, we report the synthesis and in vitro screening of a library of 1,3-oxazines, benzoxazines and quinoline scaffolds against human MRS. Among the compounds tested, 2-(2-butyl-4-chloro-1-(4-phenoxybenzyl)-1H-imidazol-5-yl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane (compound 21) and 2-(2-butyl-4-chloro-1-(4-nitrobenzyl)-1H-imidazol-5-yl)-2,4-dihydro-1H-benzo[d][1,3]oxazine (compound 8) were found to be potent inhibitors of MRS. Additionally, these compounds significantly suppressed the proliferation of A549 and HCT116 cells with IC50 values of 28.4, 17.7, 41.9, and 19.8 μM respectively. Molecular docking studies suggested that the ligand binding orientation overlaps with the original positions of both methionine and adenosine of MRS. This suggests the binding of compound 21 against MRS, which might lead the inhibitory activity towards cancer cells.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION
-
Paragraph 0108; 0109, (2015/05/05)
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing depression may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder (MDD), anxiety, neurological diseases, general anxiety disorder, social phobia, panic disorder, vasomotor symptoms, diabetic neuropathy, epilepsy, bipolar disorder, migraine, schizophrenia, cancer, menopause, HIV and familial adenomatous polyposis.
